Literature DB >> 16220517

The reassessment of trial perspectives from interim data--a critical view.

Peter Bauer1, Franz Koenig.   

Abstract

If an interim analysis is performed during a trial it is tempting to determine the conditional power to reach a rejection in the trial given the observed results in the interim analysis. Since the true effect size is unknown the conditional power may be calculated by using the effect size, which the study has been powered for in the planning phase or by using an interim estimate of the true size (or a combination of both). In either case the conditional power is a random variable and its density is investigated depending on the analysis time and the true effect size. Under the null hypothesis, in early interim analyses after a small proportion of sample units, the conditional power typically will be close to the overall power when the effect size from the planning stage is used for calculation. In this case the majority of observations must still be made and the small first-stage sample in general will be dominated by the hypothetical second-stage chance based on the wrong parameter value. It is shown that the conditional power in moderately underpowered studies can have a distribution symmetric around 0.5. When using the interim estimate for calculating the conditional power the density in general will be u-shaped. The impact of using conditional power to reassess the sample size using flexible two-stage combination tests is shown for a specific example in terms of overall power and average sample size as compared to the corresponding group sequential design. For small true effect sizes mid-trial sample size recalculation based on an interim estimate may lead to an overly large price to be paid in average sample size in relation to the gain in overall power. Finally, the problem is discussed in terms of estimating the true conditional power. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16220517     DOI: 10.1002/sim.2180

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

3.  Adaptive Budgets in Clinical Trials.

Authors:  Martin Posch; Peter Bauer
Journal:  Stat Biopharm Res       Date:  2013-04-04       Impact factor: 1.452

4.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

5.  Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.

Authors:  Dominic Magirr; Thomas Jaki; Franz Koenig; Martin Posch
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

6.  Key design considerations for adaptive clinical trials: a primer for clinicians.

Authors:  Kristian Thorlund; Jonas Haggstrom; Jay Jh Park; Edward J Mills
Journal:  BMJ       Date:  2018-03-08

7.  Interim analysis incorporating short- and long-term binary endpoints.

Authors:  Julia Niewczas; Cornelia U Kunz; Franz König
Journal:  Biom J       Date:  2019-01-29       Impact factor: 2.207

8.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

Review 9.  Critical concepts in adaptive clinical trials.

Authors:  Jay Jh Park; Kristian Thorlund; Edward J Mills
Journal:  Clin Epidemiol       Date:  2018-03-23       Impact factor: 4.790

10.  A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.

Authors:  J Bowden; A Mander
Journal:  Pharm Stat       Date:  2014-04-02       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.